Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CANCER IMMUNOLOGY

Cancer cells hijack T-cell mitochondria

Nanotube-mediated acquisition of immune cells’ mitochondria by tumour cells is a novel mechanism for immune evasion that can be pharmacologically targeted to potentiate cancer immunotherapies.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Pharmacological blockade of mitochondrial hijacking improves T-cell antitumour immunity.

References

  1. 1.

    Saha, T. et al. Nat. Nanotechnol. https://doi.org/10.1038/s41565-021-01000-4 (2021).

  2. 2.

    Bantug, G. R. et al. Nat. Rev. Immunol. 18, 19–34 (2018).

    CAS  Article  Google Scholar 

  3. 3.

    Sukumar, M. et al. Cell Metab. 23, 63–76 (2016).

    CAS  Article  Google Scholar 

  4. 4.

    Spees, J. L. et al. Proc. Natl Acad. Sci. USA 103, 1283–1288 (2006).

    CAS  Article  Google Scholar 

  5. 5.

    Berridge, M. et al. Anal. Biochem. 552, 75–80 (2018).

    CAS  Article  Google Scholar 

  6. 6.

    Mohammadalipour, A. et al. Front. Cell Dev. Biol. 8, 1519 (2020).

    Article  Google Scholar 

  7. 7.

    Burt, R. et al. Blood 134, 1415–1429 (2019).

    CAS  Article  Google Scholar 

  8. 8.

    Moschoi, R. et al. Blood 128, 253–264 (2016).

    CAS  Article  Google Scholar 

  9. 9.

    Yu, Y.-R. et al. Nat. Immunol. 21, 1540–1551 (2020).

    CAS  Article  Google Scholar 

  10. 10.

    Pilipow, K. et al. JCI Insight 3, e122299 (2018).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Luca Gattinoni.

Ethics declarations

Competing interests

L.G. has consulting agreements with Lyell Immunopharma, AstraZeneca, Turnstone Biologics, Xcelcyte. L.G. is on the scientific advisory board of Poseida Therapeutics and Kiromic, and a stockholder of Poseida Therapeutics. J.G.B. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Baldwin, J.G., Gattinoni, L. Cancer cells hijack T-cell mitochondria. Nat. Nanotechnol. (2021). https://doi.org/10.1038/s41565-021-01006-y

Download citation

Search

Quick links

Find nanotechnology articles, nanomaterial data and patents all in one place. Visit Nano by Nature Research